Slide 1: Biocon: metamorphosis into a new age drug company
$s Biocon metamorphosis into a new age drug company i i 2
Slide 2: Forward-looking statements
Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important f
Slide 3: Vision of Leadership and Excellence
Vision of Leadership and Excellence BIOTECHNOLOGY 1979 ENZYMES 1989 1994 FERMENTATION CUSTOM RESEARCH * Source: Biospectrum LEADERSHIP & EXCELLENCE ~ India’s first & No 1 Biotech company with a global Biotech ranking of 16* - Global leadership in specialty enzymes - Globally unique fermentation prof
Slide 4: Vision of Leadership and Excellence
Vision of Leadership and Excellence $ Biocon VISION LEADERSHIP & EXCELLENCE i _ = India’s largest and only USFDA qualified producer 1998 STATINS and exporter of Statins - CLINIGENE: India’s first CAP accredited Clinical 2000 CLINICAL RESEARCH Laboratory 7 - The most clinically validated r-human Insu
Slide 5: Milestones
Milestones Biocon Billion Dollar market cap on first day of listing Biocon in Top 20 Global Biotech Companies* Biocon in India's Top 5 Life Science Companies* * Source: Biospectrum & Economic Times 4 4D OP x
Slide 6: Biocon in Top Global Biotech Companies
Biocon in Top 20 Global Biotech Companies** 17 Netkar 106 (47) 1,562 18 Celera Genomics 88 (82) 791 19 ImClone Systems Inc 81 (113) 6,032 20 Exelixis Inc 51 (96) 600 * at close of trade as on July 8, 2004 ee a ae x ** Source: Biospectrum
Slide 7: Biocon in India's Top Life Science Companies
Biocon in India's Top 5 Life Science Companies* Pharmaceutical Industry Comparison Ranbaxy 963 178,753 3,909 Cipla 227 68,040 1,488 Sun 353 65,466 1,432 Dr Reddy 746 57,053 1,248 Nicholas Piramal 754 28,654 625 Wockhardt 265 «28,848 = 631 Cadila 423 26,564 581 * at close of trade as on July 8, 2004
Slide 8: Strategic Vision
Strategic Vision Biocon 1. Building strong fermentation technology platforms 2. Leveraging technology for product differentiation 3. Creating long term value through quality & innovation 4. Charting an integrated development pathway for proprietary products H4qdP wm) x
Slide 9: New drug discovery & development
s New drug discovery & : development me : » Products with large global markets » Near term patent expiry » Fermentation derived ‘ Z molecules Biopharmaceuticals - High technology barriers High regulatory barriers Generic Funding long term discovery research through a short term generic strategy * Ne
Slide 10: Leveraging Fermentation Technologies
Leveraging Fermentation Technologies Biologicals r-human Insulin Streptokinase GCSF Small Molecules h-R3 (anti-EGFR) Statins Immunosuppressants Anti-CD6 & Anti-CD 3 Cancer Vaccines EGF, TGFa, HER; Research ))) Clinical Development )) Process Development )) Commercialization H4qdP wm) x
Slide 11: Statins are the largest selling drugs in the world
de + + + Statins (anti-cholesterol) are the largest selling drugs in the world with global sales in excess of US$ 20bn The global generic market for Lovastatin, Pravastatin & Simvastatin is estimated at US$ 7bn in 2007 Biocon is the only USFDA approved producer of Lovastatin, Pravastatin & Simvastat
Slide 12: Biocon's leadership position in statins
EBiocon “* Biocon’s leadership position in this segment is supported by - USFDA & EDQM approvals - Patented / non infringing processes - Global-scale manufacturing facilities - Significant market share in key markets where the products have gone off patent - Tie-ups with a large number of Generic Co
Slide 13: Recombinant Human Insulin
Recombinant Human Insulin “© Global Sales of US$ 5 bn dominated by few players + Demand for Insulin expected to grow exponentially post approval of pulmonary Insulin (Pfizer’s Exubera) + The USFDA has stated that products like Insulin and Human growth hormone whose science has progressed far enough
Slide 14: Recombinant Human Insulin
Recombinant Human Insulin EBiocon “© Biocon is well poised to access this opportunity based on the following: - Long term supply agreement with Bristol-Myers Squibb - World class and Asia’s largest Insulin facility - Alliances with Generic Companies H4qdP wm) x
Slide 15: Monoclonal antibodies market growth
The market for monoclonal antibodies is expected to grow from US$ 4 bn in 2003 to US$ 13 bn by 2010 + Biocon is setting up Asia’s largest Monoclonal Antibody facility + The facility will manufacture hR3, an anti-EGF receptor antibody targeted against head & neck cancer as its first product followed
Slide 16: hR3 clinical trial status
Biocon Se oe The product has completed Phase I! Clinical Trials in Canada and Phase II B Clinical Trials in India are expected to commence in Q2 FY 2004-05 Proof of concept studies have indicated potential application in treatment of other cancers including brain cancer, lung cancer and breast cance
Slide 17: Capital Outlay
Capital Outlay Biocon “* Biocon has committed to invest approximately Rs 650 crores to establish the following: - Anew research facility for Syngene to double its current scientific strength - A large fermentation and synthesis facility that will quadruple existing Statins capacity - A Biologicals f
Slide 18: Managing the Future
Managing the Future Price pressure on Statins Commoditizing of Generics Potential competition in Insulin space Technology Regulatory Compliance Global Scale Capacities Strong Product Pipeline that addresses a sequential flow of new fermentation based generics Proprietary Molecules Technology Global
Slide 19: Managing the Future
Managing the Future Pace and Race for Drug Discovery is frenzied Increasing Costs of Drug Development Monoclonal Antibodies and Cancer » >> Vaccines are the most promising front runners in the approval pipeline NS Integrated Model provides speed and » cost advantage H4qdP wm) x
Slide 20: Key Growth Drivers in Q1 2004-05
Key Growth Drivers in Q1 2004-05 $Biocon “> Successful market entry of Pravastatin in Europe post patent expiry in key markets in Europe increased supply of Lovastatin to US post USFDA approval of additional statin facilities Increase in Syngene’s research services H4qdP wm) x
Slide 21: Key Developments in Q1 2004-05
Key Developments in Q1 2004-05 EBiocon “* Product portfolio of BBPL expanded to include the following products: 1. h-T1, a humanized anti-CD6 targeting immuno-suppressive monoclonal antibody for T-cell Lymphoma, Rheumatoid Arthritis and Psoriasis. 2. q-T3, a chimeric anti-CD3 targeting immuno-suppre
Slide 22: Financials
ade FINANCIALS 4 4 bP) PE Xx
Slide 23: Revenue by segment
(Rs. mm) 1,076 Z- ™~ (Revenue growth 65% y) QIFY 04 G3 Custom Research @BEnzymes nar QIFYOS Pharma BBOther income MH Total a 4) x
Slide 24: Revenue Growth
Revenue Growth $ Biocon Dynamics Customresearch 80% 8 Significant expansion of revenues from both existing & new customers Enzymes 8 Speciality Enzymes continue to generate significant interest in US & Europe Pharma Others 8 Introduction of Tacrolimus & Commencement of supply of Domestic Formulation
Slide 25: Domestic and export revenues
1,128 (1) As per indian GAAP finanxisk 720 614 354 QIFY 04 QTFY 0S G Domestic GB Exports I< eA | x
Slide 26: Q1 FY05 profit and loss summary
$ Biocon / Qi FY 04 Fee Q1 FY 05 Revenues 1,076 1,779 EBDITA 352 573 PBT 305 520 PAT 229 486 Profit Growth - 112% (1) As per Indian GAAP finanxials % to 32 29 27 - Improved Yields & Sales Mix - Growth in Personnel & Salary Increment ~ Exchange Loss & Increase in SG&A Exps ~ Profits from 100% EOUs no
Slide 27: Balance sheet
Shareholder Funds 1,575 6,122 Deferred Tax 152 185 Loan Funds 773 935 Total 2,500 7,242 Net Fixed Assets 1,567 2,619 Investments + Cash in Bank 87 3,603 Net Working capital 846 1,020 Total 2,500 7,242 ] (1) As per Indian GAAP financials Ly He A | x
Slide 28: Cash flow
$ Biocon Operations 68 291 Capex + Investments (157) (3,711) Financing Activities 80 265 (1) As per Indian GAAP financials I< 4D OP x
Slide 29: Thank You
Thank You MS Fm x